StockNews.com started coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
A number of other research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Concert Pharmaceuticals in a report on Friday, March 4th. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $9.81.
CNCE stock opened at $4.49 on Friday. The stock has a market capitalization of $163.12 million, a price-to-earnings ratio of -1.69 and a beta of 0.40. Concert Pharmaceuticals has a 1 year low of $2.57 and a 1 year high of $5.00. The stock’s fifty day moving average is $3.46 and its two-hundred day moving average is $3.37.
Several institutional investors have recently made changes to their positions in CNCE. Virtu Financial LLC acquired a new stake in Concert Pharmaceuticals in the 1st quarter worth approximately $47,000. Jane Street Group LLC bought a new position in Concert Pharmaceuticals in the 1st quarter worth approximately $56,000. State Street Corp increased its position in Concert Pharmaceuticals by 7.2% in the 1st quarter. State Street Corp now owns 75,798 shares of the biotechnology company’s stock worth $255,000 after buying an additional 5,058 shares during the period. Charles Schwab Investment Management Inc. bought a new position in Concert Pharmaceuticals in the 1st quarter worth approximately $80,000. Finally, Parkman Healthcare Partners LLC bought a new position in Concert Pharmaceuticals in the 1st quarter worth approximately $1,272,000. Institutional investors and hedge funds own 51.26% of the company’s stock.
Concert Pharmaceuticals Company Profile (Get Rating)
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.
- Get a free copy of the StockNews.com research report on Concert Pharmaceuticals (CNCE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.